[Mexican National Consensus on Assisted Reproduction Treatment].
暂无分享,去创建一个
A. Kably Ambe | C. Serviere Zaragoza | F. Gaviño Gaviño | E. Pérez Peña | C. L. López Ortiz | G. Velázquez Cornejo | Roberto Santos Haliscack | Martha Luna Rojas | E. Valerio | H. Santana
[1] N. Macklon,et al. Peri-implantation glucocorticoid administration for assisted reproductive technology cycles. , 2012, The Cochrane database of systematic reviews.
[2] E. Kolibianakis,et al. Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis. , 2011, Human reproduction update.
[3] S. Muasher,et al. Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited. , 2011, Fertility and Sterility.
[4] H. Tournaye,et al. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. , 2011, Fertility and sterility.
[5] M. Eijkemans,et al. Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. , 2011, Human reproduction update.
[6] S. Silber,et al. Minimal ovarian stimulation (mini-IVF) for IVF utilizing vitrification and cryopreserved embryo transfer. , 2010, Reproductive biomedicine online.
[7] P. Humaidan,et al. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. , 2010, Fertility and sterility.
[8] B. Urman,et al. Effect of energy expenditure and physical activity on the outcomes of assisted reproduction treatment. , 2010, Reproductive biomedicine online.
[9] L. Nardo,et al. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. , 2008, Fertility and sterility.
[10] N. Macklon,et al. Does glucocorticoid therapy in the peri-implantation period have an impact on IVF outcomes? , 2008, Current opinion in obstetrics & gynecology.
[11] J. Nulsen,et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. , 2008, Fertility and sterility.
[12] R. Frydman,et al. The ISMAAR proposal on terminology for ovarian stimulation for IVF. , 2007, Human reproduction.
[13] E. Kolibianakis,et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. , 2007, Human reproduction update.
[14] C. Simón,et al. Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction , 2007 .
[15] N. Amso,et al. Embryo freezing for preventing ovarian hyperstimulation syndrome. , 2007, The Cochrane database of systematic reviews.
[16] O. Kato,et al. Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective study. , 2007, Reproductive biomedicine online.
[17] J. Tesarik,et al. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. , 2006, Human reproduction.
[18] J. Donnez,et al. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. , 2006, Human reproduction.
[19] M. Huleihel,et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. , 2006, Human reproduction.
[20] V. Alam,et al. Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients , 2006, Current medical research and opinion.
[21] G. Serour,et al. Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis. , 2005, Human reproduction.
[22] S. Oehninger,et al. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. , 2005, Fertility and sterility.
[23] R. Orvieto,et al. Immediate ambulation after embryo transfer: a prospective study. , 2005, Fertility and sterility.
[24] R. Will,et al. Creutzfeldt-Jakob disease and urinary gonadotrophins. , 2004, Human reproduction.
[25] J. Tesarik,et al. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. , 2004, Human reproduction.
[26] M. Eijkemans,et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with rec , 2003, The Journal of clinical endocrinology and metabolism.
[27] Yu-Hung Lin,et al. Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles. , 2003, Human reproduction.
[28] A. Atwood,et al. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. , 2002, Human reproduction.
[29] D. Seifer,et al. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. , 2002, Fertility and sterility.
[30] P. Devroey,et al. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. , 2001, Human reproduction.
[31] S. Oehninger,et al. Impact of different clinical variables on pregnancy outcome following embryo cryopreservation , 2000, Molecular and Cellular Endocrinology.
[32] M. Bahçeci,et al. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. , 2000, Human reproduction.
[33] J. Hill,et al. Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols? , 1999, Human reproduction.
[34] N. Gleicher,et al. A rational approach to the management of low responders in in-vitro fertilization. , 1999, Human reproduction.
[35] J. Donnez,et al. Outcome of in-vitro fertilization through natural cycles in poor responders. , 1999, Human reproduction.
[36] J. Stanger,et al. Ultrasound tracking of the movement of embryo-associated air bubbles on standing after transfer. , 1998, Human reproduction.
[37] S. Oehninger,et al. Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. , 1998, Fertility and sterility.
[38] B. Fauser,et al. Manipulation of human ovarian function: physiological concepts and clinical consequences. , 1997, Endocrine reviews.
[39] H. Martikainen,et al. Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro fertilization. , 1997, Human reproduction.
[40] G. Lambert-Messerlian,et al. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. , 1997, Fertility and sterility.
[41] S. Campbell,et al. Relationship of Ovarian Stromal Blood Flow at the Baseline Ultrasound Scan to Subsequent Follicular Response in an In Vitro Fertilization Program , 1996, Obstetrics and gynecology.
[42] P. Kroboth,et al. Oral Administration of Micronized Progesterone: A Review and More Experience , 1996, Pharmacotherapy.
[43] E. Atkinson,et al. Minimal stimulation achieves pregnancy rates comparable to human menopausal gonadotropins in the treatment of infertility. , 1996, Fertility and sterility.
[44] B. V. Van Voorhis,et al. Ovarian volume: a novel outcome predictor for assisted reproduction. , 1995, Fertility and sterility.
[45] D. Navot,et al. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. , 1994, Fertility and sterility.
[46] M. Milad,et al. A novel ovarian stimulation protocol for use with the assisted reproductive technologies. , 1993, Fertility and sterility.
[47] N. Laufer,et al. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment , 1993 .
[48] S. Muasher. Use of gonadotrophin-releasing hormone agonists in controlled ovarian hyperstimulation for in vitro fertilization. , 1992, Clinical therapeutics.
[49] S. Oehninger,et al. The gonadotropin-releasing hormone agonist stimulation test--a sensitive predictor of performance in the flare-up in vitro fertilization cycle. , 1991, Fertility and sterility.
[50] B. Martin-Pont,et al. Interest of growth hormone-releasing hormone administration for improvement of ovarian responsiveness to gonadotropins in poor responder women. , 1991, Fertility and sterility.
[51] G. Jones,et al. High‐dose follicle‐stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low‐responder patients , 1991, Fertility and sterility.
[52] R. Casper,et al. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. , 1990, The Journal of clinical endocrinology and metabolism.
[53] J E Garcia,et al. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. , 1990, Fertility and sterility.
[54] J. Garcia,et al. Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization. , 1990, Fertility and sterility.
[55] D. Meldrum,et al. Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. , 1989, Fertility and sterility.
[56] Z. Rosenwaks,et al. The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. , 1988, Fertility and sterility.
[57] Z. Rosenwaks,et al. PROGNOSTIC ASSESSMENT OF FEMALE FECUNDITY , 1987, The Lancet.
[58] A. Ferraretti,et al. Serum luteinizing hormone during ovulation induction with human menopausal gonadotropin for in vitro fertilization in normally menstruating women. , 1983, Fertility and sterility.